📊 RGPX Key Takeaways
Is Regenerex Pharma, Inc.. (RGPX) a Good Investment?
REGENEREX PHARMA is financially insolvent with negative stockholders equity of -4.7M, liabilities of 5.3M against only 617.8K in assets, and a critically depleted cash position of 11.7K. The company is burning nearly 1M in annual operating cash flow while generating virtually no revenue (1.8K), indicating complete operational failure and imminent solvency crisis.
RGPX shows severe fundamental weakness: negligible revenue, extreme negative margins, persistent losses, and negative equity. Liquidity is critically constrained (cash ~$11.7K, current ratio 0.01x) amid heavy operating cash burn, indicating urgent financing needs. Without a credible path to revenue and recapitalization, insolvency or highly dilutive funding is likely.
Regenerex Pharma, Inc.. Key Strengths (RGPX)
- Company still maintains legal entity status and SEC filing capability
- Debt load of 184.2K, while significant relative to assets, is not massive in absolute terms
- No material liabilities from failed clinical trials or major product recalls noted
- Asset-light model with minimal capex needs
- YoY improvement in net loss (+28.7%)
- Modest long-term debt balance
RGPX Stock Risks: Regenerex Pharma, Inc.. Investment Risks
- Negative stockholders equity of -4.7M indicates technical insolvency and bankruptcy risk
- Critical liquidity crisis with current ratio of 0.01x and only 11.7K cash against 5.3M liabilities
- Revenue has collapsed 31.9% YoY to negligible 1.8K, indicating no active commercial products or operations
- Severe cash burn of 997.3K annually with minimal cash reserves suggests runway of days, not months
- Zero insider trading activity suggests management lacks confidence in company viability
- Deeply negative margins across all metrics with operating losses of 1.4M on near-zero revenue
- Acute liquidity shortfall (0.01x current ratio; minimal cash)
- Negative equity with high liabilities; going-concern risk
- Large cash burn and negligible revenue imply dilution/insolvency risk
Key Metrics to Watch
- Stockholders equity trend - if becomes more negative, insolvency accelerates
- Cash balance - runway until complete depletion at current burn rate
- Revenue - any commercial traction would indicate operational restart
- Cash & Equivalents
- Operating Cash Flow
Regenerex Pharma, Inc.. (RGPX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RGPX Profit Margin, ROE & Profitability Analysis
RGPX vs Healthcare Sector: How Regenerex Pharma, Inc.. Compares
How Regenerex Pharma, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Regenerex Pharma, Inc.. Stock Overvalued? RGPX Valuation Analysis 2026
Based on fundamental analysis, Regenerex Pharma, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Regenerex Pharma, Inc.. Balance Sheet: RGPX Debt, Cash & Liquidity
RGPX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Regenerex Pharma, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
RGPX Revenue Growth, EPS Growth & YoY Performance
RGPX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | $181 | -$33.7K | N/A |
| Q2 2021 | $120 | -$9.8K | N/A |
| Q1 2021 | $77 | -$9.8K | N/A |
| Q3 2020 | $181 | -$20.6K | N/A |
| Q2 2020 | $120 | -$9.8K | N/A |
| Q1 2020 | $77 | -$9.8K | N/A |
| Q3 2019 | $1.7K | -$20.6K | N/A |
| Q3 2014 | $9.2K | -$59.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Regenerex Pharma, Inc.. Dividends, Buybacks & Capital Allocation
RGPX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Regenerex Pharma, Inc.. (CIK: 0001357878)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RGPX
What is the AI rating for RGPX?
Regenerex Pharma, Inc.. (RGPX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RGPX's key strengths?
Claude: Company still maintains legal entity status and SEC filing capability. Debt load of 184.2K, while significant relative to assets, is not massive in absolute terms. ChatGPT: Asset-light model with minimal capex needs. YoY improvement in net loss (+28.7%).
What are the risks of investing in RGPX?
Claude: Negative stockholders equity of -4.7M indicates technical insolvency and bankruptcy risk. Critical liquidity crisis with current ratio of 0.01x and only 11.7K cash against 5.3M liabilities. ChatGPT: Acute liquidity shortfall (0.01x current ratio; minimal cash). Negative equity with high liabilities; going-concern risk.
What is RGPX's revenue and growth?
Regenerex Pharma, Inc.. reported revenue of $1.8K.
Does RGPX pay dividends?
Regenerex Pharma, Inc.. does not currently pay dividends.
Where can I find RGPX SEC filings?
Official SEC filings for Regenerex Pharma, Inc.. (CIK: 0001357878) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RGPX's EPS?
Regenerex Pharma, Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RGPX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Regenerex Pharma, Inc.. has a D grade with 96% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RGPX stock overvalued or undervalued?
Valuation metrics for RGPX: ROE of N/A (sector avg: 15%), net margin of -83,244.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RGPX's AI grade for 2026?
Our dual AI analysis gives Regenerex Pharma, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RGPX's free cash flow?
Regenerex Pharma, Inc..'s operating cash flow is $-997.3K, with capital expenditures of N/A. FCF margin is -56,185.8%.
How does RGPX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -83,244.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.01 (avg: 2).